Abstract
This study aimed to identify hub genes and drugs for ovarian cancer (OC) using bioinformatics analysis. Gene expression data and clinical information were downloaded from public databases. Differentially expressed genes (DEGs) were identified, and ovarian disease-related genes were extracted from DISEASES database. Disease-associated DEGs were further screened. Functional enrichment, protein–protein interaction (PPI) analysis, drug prediction, and survival analysis were performed. Key gene-drug interactions were also predicted. Finally, hub genes expression in an OC cell line (SKOV3) was verified using real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR). Totally 354 overlapping DEGs were identified. PPI network revealed genes such as CCL5 and CXCR4 with higher degrees, which were mainly involved in chemokine-related functions. CCND1, CCNE1, CXCL10, ERBB4, LPAR3, and SST were correlated with prognosis of OC patients. Among them, CXCL10 was considered as an independent prognostic factor. Moreover, 63 possible drugs were predicted and the sirolimus-DCN pair was screened via a literature search. RT-qPCR confirmed that the levels of PDGFRB, DCN, PDGFRA, LYN, and CENPE were consistent with the bioinformatics analysis results. Our findings provide new insights into the underlying mechanisms of OC pathogenesis. The identified hub genes and drugs may improve individualized OC diagnosis and therapy.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
